Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from diabetes

What Happens to Your Blood Sugar When You Walk After Dinner?

Dinner is over, the dishes are stacked by the sink, and the couch probably looks considerably more inviting than your walking shoes. But spending even...

Saving Advice · 6h ago

Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss

Rhode Island Medicaid stopped covering Wegovy, Zepbound, Saxenda, and Foundayo for weight loss on Oct. 1, 2026. Diabetes coverage continues. Here is what members should know.

Medical Daily · 8h ago

Liver Fat Fell to Normal in 23 of 26 Adults with Obesity in Small Wegovy Post Hoc Analysis

In a small Novo Nordisk analysis, 23 of 26 adults with obesity and excess liver fat reached normal levels on semaglutide. Here is what the numbers do and do not show.

Medical Daily · 8h ago

From analysis to the latest developments in health,
read the most diverse news in one place.

Can Heart Disease Increase Your Kidney Disease Risk?

We often think of the heart, lungs and kidneys as completely separate parts of the body. But your organs work as a connected system, and trouble in one area can sometimes affect another. Heart disease and kidney disease, for example, share several risk factors and can influence each other over…

MyLifeXP · 16h ago

Lilly's Foundayo Pill Linked to 57% Lower Predicted Diabetes Risk in ATTAIN-1 Modeling, but No Cases Were Counted

A Lilly-funded modeling analysis tied Foundayo to a 57% lower predicted 10-year diabetes risk. No actual diabetes cases were counted in the study.

Medical Daily · 18h ago

The Pituitary Tumor Behind a Woman's Cushing's Syndrome Was Hiding in Her Cheek Sinus

A hormone-making pituitary tumor behind a woman's Cushing's syndrome turned up in her maxillary sinus after a pituitary scan pointed elsewhere.

Medical Daily · 19h ago

Pregnant While Taking Ozempic or Mounjaro? Large Review Offers Early Reassurance, but Stopping Before Pregnancy Is Still Advised

A review of 43,000+ women found no clear link between GLP-1 drugs and major pregnancy complications. Labels still say to stop before a planned pregnancy.

Medical Daily · 20h ago

Read news from The Economist, FT, and more,
with one subscription

Peer-Reviewed Retatrutide Data Show 23.4% Weight Loss in Adults with Diabetes and BMI of 35 or Higher

Full Lancet results for Lilly's retatrutide show 23.4% weight loss in adults with type 2 diabetes and a BMI of 35 or higher. The drug remains unapproved.

Medical Daily · Oct 2

Participants Taking CagriSema Showed Changed Brain Responses to High-Calorie Food Images in Novo Study as FDA Decision Nears

Novo says brain scans showed CagriSema changed food-cue responses and cut cravings. The data are early, and an FDA decision is expected in late 2026.

Medical Daily · Oct 2

79 deaths a day: South Africa’s diabetes crisis needs a new strategy

Statistics South Africa (Stats SA) recently released its report on deaths that occurred in 2024. The headline findings contain a sobering, recurring truth: diabetes was once again the country’s leading underlying natural cause of death.

The Conversation · Oct 2

7 Shocking Ways Sitting All Day Hurts Your Heart

You may finish an eight-hour workday without feeling tired, but your heart may still be paying the price. Sitting at a desk, driving home, eating dinner and then relaxing on the sofa can turn most of your waking hours into sedentary time. The World Health Organization links higher amounts of…

MyLifeXP · Oct 2

Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 Diabetes

Lilly's eloralintide plus tirzepatide produced 23.3% weight loss vs 14.8% for tirzepatide alone in a Phase 2 diabetes trial. Here's the catch.

Medical Daily · Oct 2

Lilly's Foundayo Pill Matched Insulin on Heart Safety in Lancet Trial, but Its Lower Death Rate Needs Caution

Lilly's Foundayo pill met a heart-safety test against insulin in a Lancet trial. Fewer deaths were seen, but that result is secondary.

Medical Daily · Oct 2

Experimental Survodutide Cut Weight Up to 13.1% in Adults with Type 2 Diabetes in Boehringer's Phase 3 Trial

Survodutide cut weight by up to 13.1% in adults with type 2 diabetes in a company-funded trial. It is not approved, and 18% quit due to side effects.

Medical Daily · Oct 2

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK · Oct 1

More new US moms are taking GLP-1 drugs

But data on taking the drugs during breastfeeding remains limited

Medical Daily · Oct 1

Youth Diagnosed with Type 2 Diabetes Before 20 Had Twice the ADHD Rate of Peers in Early Data

In a 4.2-million-patient U.S. records analysis, 14.4% of people with type 2 diabetes before age 20 had ADHD vs. 6.9% of peers. What parents should know.

Medical Daily · Oct 1

Lancet Publishes Full Petrelintide Trial: About 10% Weight Loss, Nausea in 20% as Amylin Drug Enters Phase 3

Full Phase 2 results for petrelintide in The Lancet show about 10% weight loss and nausea in 20%. What the experimental amylin drug means for patients.

The Independent UK · Oct 1

New weight loss drug combination helps patients lose 54 pounds in less than a year

Combining Mounjaro and Elora helped patients to shed almost a quarter of their body weight on average

Get all your
news in one place.

100's of premium titles.
One news app.

Times Life · Oct 1

5 Rules for Fasting Safely When You Take Diabetes or BP Medication

Why Medication Changes Everything About FastingMost people who fast do so without a second thought about timing. But if you take insulin, sulphonylureas such as glipizide or glibenclamide, or certain blood pressure drugs, an empty stomach is not neutral. Sulphonylureas lower blood glucose whether or not you have eaten, which…

Times Life · Oct 1

Kuttu vs Singhara vs Wheat Atta: Which Flour Spikes Blood Sugar Less

Why Flour Choice Affects Blood Sugar at AllWheat atta raises blood sugar through starch, specifically, how quickly its starch breaks down into glucose in the small intestine. The speed of that breakdown is what the glycaemic index measures. A flour with a lower GI releases glucose more slowly, producing a…

Medical Daily · Oct 1

AI Voice Screen Caught 82% of Type 2 Diabetes Cases but Falsely Flagged 47% of People Without It

An AI tool that analyzes 20 seconds of speech caught 82% of type 2 diabetes cases in a UK study but wrongly flagged 47% of people without it.

Medical Daily · Oct 1

Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly's Indirect Type 2 Diabetes Analysis

Lilly's indirect analysis found Foundayo 17.2 mg edged oral semaglutide 25 mg on weight and A1C in type 2 diabetes, but the gaps were modest.

Medical Daily · Sep 30

Novo-Funded Analysis Ties Raising Ozempic to 2 mg to Slightly Lower Heart Risk Than Switching to Mounjaro

A Novo-funded claims analysis tied raising Ozempic to 2 mg with 6% lower heart risk than switching to Mounjaro. Here is why confounding matters.

Medical Daily · Sep 30

Ozempic Users Worried About Pancreatic Cancer Get Reassuring Nordic Registry Data, but Follow-Up Lasted Under Two Years

A Novo-funded Nordic study of 97,464 semaglutide users found no rise in pancreatic cancer, but follow-up lasted under two years after a lag.

The Economic Times · Sep 30

Who is Veeramachineni Ramakrishna? Famous social media personality known for his VRK diet, booked in fake-doctor fraud case after law student hospitalized following his diet

Hyderabad police have registered a case against Veeramachineni Ramakrishna, also known as VRK, and Dr. Koteshwara Rao. These individuals face allegations for providing unauthorized medical advice regarding diabetes and other conditions. A law student claims he was advised to stop taking insulin, leading to hospitalization with diabetic ketoacidosis. The Healthcare…

1 2 3 4 5

Coverage From

Organisations

the World Health Organization

the American Heart Association

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.